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 ABBREVIATIONS AND ACRONYMS 
 
 SUA   - Serum Uric Acid  
 HTN  - Hypertension  
 DM   - Diabetes Mellitus  
 Met S   - Metabolic Syndrome  
 CT   - Computerized tomography  
 Echo   - Echocardiogram  
 ECG   - Electrocardiogram  
 CVA   - Cerebro Vascular Accident  
 CV Risk  - Cardio Vascular Risk  
 NO   - Nitric Oxide  
 IR   - Insulin Resistance  
 IFG   - Impaired Fasting Glucose  
 IGT   - Impaired Glucose Tolerance 
  
BACKGROUND AND OBJECTIVE : 
               Stroke is a major cause of mortality and morbidity throughout the world. Apart 
from the traditional risk factors of stroke many reports have suggested that hyperuricemia 
plays an important prognostic role in cerebrovascular accidents. The objective of this 
study was to evaluate the role of serum uric acid (SUA) as an independent risk factor for 
non-embolic ischemic stroke. 
METHODOLOGY : 
                100 patients presenting with first episode of acute non-embolic ischemic stroke 
were included in the study. Patients with history of renal failure, gout, previous stroke 
and thiazide diuretic intake were excluded from the study. Patients presenting with 
hemorrhagic stroke and embolic stroke were also excluded from the study. SUA was 
measured using a standard analyzer. Patients were also evaluated for the presence of 
additional risk factors. 
RESULTS : 
                The mean age of the study population was 59.84 years. Mean level of SUA in 
males was 5.39mg/dl and females was 5.51mg/dl. The mean SUA level was 6.10mgs/dl 
among diabetics and 4.86mgs/dl among non-diabetics showing a strong association 
(p<0.05) between SUA and diabetes mellitus. The mean SUA value for 40-49 yrs age 
group was 4.34 mg/dl while the elderly age group of above 70 yrs had a mean SUA value 
6.65 mg/dl showing a strong association (p<0.05) between increasing age and SUA. A 
strong association was also found between SUA and cardiovascular diseases. 
 
CONCLUSION : 
 
                This study shows that elevated SUA is strongly associated with an increased 
risk for the development of acute ischemic / non-embolic stroke in this study population. 
The association between elevated SUA and ischemic stroke may need to be considered 
especially when treating elderly patients, diabetics and the population with coronary 
artery disease. Lowering SUA level can be considered as one of the preventive modalities 
for stroke while treating high risk population. 
  
KEYWORDS : 
                 ischemic stroke, hyperuricemia, diabetes mellitus 
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INTRODUCTION 
 
 Among all the neurological diseases of adult life, the cerebrovascular 
(CV) diseases clearly rank the first in frequency and importance. At least 
50% of the neurological disorders in a general hospital are of this type. 
Stroke is the third most common cause of death next only to cardiovascular 
diseases and malignancies.  
            In the developed countries among the 700000 cases of stroke, 
roughly 600000 are ischemic lesions. All the physicians have a 
responsibility to prevent the incidence of stroke by encouraging the control 
of risk factors (1). Stroke also poses a high socio economic stress on the 
society due to the associated morbidity and mortality (2). Ischemic strokes 
account for three fourths of the stroke burden. Primary prevention by early 
recognition of people at risk and prevention of emergence of risk factors is 
of utmost importance nowadays (3).  
 Uric Acid is an aqueous antioxidant in humans, and is involved in 
almost 70% of  the free radical scavenging reactions in the humans. It is 
specifically involved in neutralizing  peroxynitrite, hydroxyl, and superoxide 
radicals. It also plays a major role in prevention of lipid peroxidation (34). 
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             During episodes of ischemic events and oxidative stress due to 
various causes the levels of local uric acid concentration elevates as a 
protective mechanism (64). During experimentation in animals uric acid 
levels were found to elevate substantially in response to adverse brain events 
(62). Such experiments in lab animals involving  middle cerebral artery 
occlusion lead to a dramatic elevation of local Uric Acid levels, which 
remained elevated for a significant period of time following the event (63). 
These findings have invoked interest in the prognostic value and uses of 
elevated  Uric Acid levels in the event of an acute ischaemic stroke.  
 The importance of serum uric acid (SUA) levels as an independent 
risk factor for stroke is being analyzed recently  (4). Epidemiological 
research has provided substantial evidence that high SUA levels can predict 
the susceptibility for adverse cerebrovascular events like stroke (4-6). 
Recently therapeutic interventions with a SUA lowering effect have been 
proved to significantly decrease CV disease morbidity and mortality (8).  
 Diabetes mellitus confers a two fold to four fold higher risk of the 
incidence of an adverse vascular event including  cerebro vascular accidents 
(10). This increased risk has only been partially attributed to the pathologic 
effects of diabetes on  risk factors associated with hyperinsulinemia (10). 
SUA has been recently associated with insulin resistance (11). One study 
(10) indicates hyperuricemia is a useful predictor of cerebrovascular events 
in elderly diabetic patients independent of the remaining CV risk factors.  
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 Though it has been recognised as an important risk factor for 
cerebrovascular events in many research studies (4-7), it is yet to be 
confirmed whether high SUA levels have an important role in the 
etiopathogenesis  of  Cerebrovascular disease or if it is just a co-incidental 
finding(12). Studies like NHANES I  have provided data to support a 
positive association between SUA and stroke in middle age people, after 
accounting for other confounding factors (13).  
 So elevated SUA levels can be quite useful for predicting  patients at 
risk for adverse cerebrovascular events and to start primary preventive 
measures(9).  
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REVIEW OF LITERATURE 
 
URIC ACID     
 
 
          Uric acid (C3H4N4O3:2,6,8 TRIOXY PURINE) is a weak organic 
acid ionised at position 9 with functional pKa in serum of 5.75. It is  the final 
end product of purine metabolism in human beings.  Uric acid has two forms 
depending  on the pH. At the pH of 7.4 of most body fluids it exists as urate 
ion in the ratio of 50:1 to uric acid. 
In acidic pH like urine at pH of 5.0 it is soluble and exist as uric acid. 
In serum the urate ion bind with the extracellular Na ion and forms 
monosodium urate. 
Uric acid was first identified 200 years back. But its pathophysiologic 
aspects and functions in human beings is unclear. 
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Based on excretion of nitrogenous wastes organisms are classified as  
1.ureotelic. 
2.ammoniotelic. 
3.uricotelic.  
Ureotelic are those animals that excrete nitrogenous wastes in the 
form of urea. for example most of vertebrates. Ammoniotelic are the 
organisms that excrete NH4 ion and rely on aquatic environment for dilution 
of toxic substances. Uricotelic are those who excrete uric acid. For example 
primates,birds and reptiles.  
Mammals other than primates oxidize uric acid to allantoic acid by 
the enzyme uricase. This allantoic acid is further processed to urea in bony 
fishes. This urea is still excreted in invertebrate aquatic organisms as NH4 
ion. 
When compared with lower invertebrate animals most of vertebrates 
and mammals are having high uric acid handling capacity and much 
increased urate level in blood. It may be a part of evolution as urate is a 
highly effective scavenger of reactive oxygen species and acts as an  
effective antioxidant. It may be one of the reasons for increased life span 
when compared with those of  aquatic animals. Also excretion of uric acid 
doesn’t need much of water when compared to its metabolite products. So 
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by excreting as such humans can conserve water.  In humans the fractional 
excretion of  uric acid is low. 
Approximately 75% of uric acid is produced endogenously through 
cell breakdown and remaining 25% by dietary purines. Among these two 
third is excreted through kidney and one third through intestine. 
Foods high in purine 
Meat Fish Vegetables Others 
Liver 
Kidney 
Heart 
Red meat 
Poultry 
 
Anchovies 
Herring 
Sardines 
Mackerel 
Shell fish 
Mussels 
Shrimp 
 
Peas 
Legumes 
Spinach 
Lentils 
Beans 
Asparagus 
Cauliflower 
Mushrooms 
Yeast 
Nuts 
Alcohol  
Beer 
Wine  
 
                Decreased purine intake for 10 days will reduce urate level in 
blood by 25% and in urine by 50%. Total serum urate level in men  is 800-
1500 mg and in women it is 500-1000mg. Diets rich in cow’s milk and vit-c 
decrease uric acid. 
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Endogenously there are  two cycles of purine metabolism. 
o De novo pathway 
o Salvage pathway 
 
The important enzymes for clinical implications in these cycles are  
1. Inosine mono phosphate 
2. Adenosine deaminase 
3. Hypoxanthine-guanine phosphor ribosyltransferase. 
         
             SALVAGE  PATHWAY 
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             DE NOVO PATHWAY OF PURINE SYNTHESIS 
 
 
             The synthesised purines are degraded  by xanthine oxidase (which is 
the enzyme targeted by allopurinol) to uric acid. The enzyme xanthine 
oxidase is  a molybdenum –pterin- ferrous sulphide- flavoprotein.  
 The formed uric acid is  predominantly excreted by kidney. Uric acid 
undergoes 4 processes in  kidney. 
 1.glomerular filtration 
 2.urate reabsorption 
 3.tubular secretion  
 4.post secretory reabsorption. 
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There are two important channels for urate transportation in the  kidney. 
                  Two of these transporters, glucose transporter 9 (GLUT9) and 
urate transporter 1 (URAT1), are members of the organic acid transporter 
(OAT) family and have strong effects on serum urate levels. 
 
GLUT –9 transport: 
 GLUT-9 transporter is predominantly a product of SLC2A9 gene. It is 
a voltage dependent urate transporeter which mediates urate reabosrption. 
           It has two isoforms. GLUT-9L seen in basolateral side of proximal 
convoluted tubule and GLUT-9S in apical side. This GLUT-9 is the target 
for probenecid and benzbromarone and increase uric acid excretion. 
Different mutations of SLC2A9 cause renal hypouricemia. 
          As with URAT1, mediation of urate reabsorption by GLUT9 is 
inhibited by the uricosuric agents probenecid and benzbromarone. 
         GLUT9 is also expressed in the basolateral membrane of hepatocytes 
and regulates serum urate concentrations through dual roles in urate handling 
in the kidney and uptake in the liver. Mice with systemic “knockout” of 
GLUT9 have moderate hyperuricemia, massive hyperuricosuria, and early 
onset nephropathy. In contrast, specific inactivation of the GLUT9 gene in 
the liver of adult mice leads to severe hyperuricemia and hyperuricosuria, 
but without the renal disease. 
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             GLUT9 also transports the sugars glucose and fructose, which may 
be pertinent to the dietary influences of these compounds on hyperuricemia 
and gout. A substantial role for GLUT9 in the physiologic regulation of 
serum or plasma urate levels is further suggested by the results of genome-
wide association and candidate gene studies. Such studies show that the 
SLC2A9 locus and certain polymorphisms are associated with an increased 
risk for hyperuricemia and gout. Different mutations of SCL2A9 have also 
been linked with renal hypouricemia, particularly in patients with intact 
URAT1. 
 
URAT-1 transporter: 
             This transporter is highly specific for uric acid.  It can transport uric 
acid in both directions across the tubular membrane depending on the uric 
acid concentration. It is a product of SLC22A12 gene and belongs to OAT 
family. This channel is also seen in the apical membrane of proximal 
convoluted tubules. It is also inhibited by uricosuric drugs like probenecid. 
Mutation in the gene encoding Urat-1 transporter causes hyperuricosuria, 
hypouricemia 
             URAT1 is encoded by the SLC22A12 gene and has a typical OAT 
structure. URAT1 is highly specific for urate. It mediates the exchange of 
urate for a variety of endogenous and drug anions known to affect renal uric 
acid transport. 
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            URAT1 can transport urate in either direction across the tubular cell 
membrane, depending on the relative concentrations of urate and other ions 
on each side of the membrane. Like GLUT9S, URAT1 localizes to the apical 
brush border membrane of proximal tubular epithelial cells. 
            URAT1 is important in the renal regulation of serum urate levels in 
normal individuals. The uricosuric drugs probenecid, benzbromarone, and 
lesinurad increase urate excretion by inhibiting URAT1 and other OATs. 
Urate transporters may also play other roles in urate metabolism, for 
example, in the transport of urate across hepatic cell membranes. 
            URAT1 interacts with the scaffolding protein PDZK1. PDZ motifs 
are typically involved in the protein-protein interactions that support 
intracellular signaling and are also present in other urate transporters, 
including OAT4 and NPT1 . This suggests that a more extensive 
multiprotein complex the “urate transportasome,” which contains transport 
regulatory molecules, hormone receptors, and intracellular signaling 
elements may be involved in regulated bidirectional transport of urate across 
the renal tubular epithelial cell.          
                Fractional renal excretion of urate  (FEua = uric acid 
clearance/creatinine clearance × 100) in URAT1 knockout mice remains 
substantially less than 100%. This confirms that there are multiple 
mechanisms of uric acid reabsorption. 
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Other urate transporters: 
 1.ABCG 2  
 2.NPT 1 and NPT 4 
 3.OAT 4 
 4.OAT 10. 
 
 
URATE TRANSPORTERS IN THE KIDNEY 
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STROKE (68) 
 
 A stroke (Struck by the Hand of God) or cerebrovascular accident 
(CVA) is defined as the abrupt onset of a neurological deficit that is 
attributable to a focal vascular cause. The clinical manifestations of stroke 
are highly variable because of the complex anatomy of brain and its 
vasculature.  
 
 Cerebral ischaemia is caused by a reduction in blood flow that lasts 
longer than several seconds. Neurological symptoms manifest within 
seconds because neurons lack glycogen, so energy failure is rapid. A TIA or 
transient ischemic attack is a temporary sudden onset neurological deficit  
due to focal ischemia of brain for a duration of less than 24 hours. If the 
ischemia and deficit lasts for a period more than 1 hour, it may probably be 
due to small infarctions.  Stroke has occurred if the neurological signs and 
symptoms last for  >24hrs.  
 
 Focal ischaemia or infarction is usually caused by thrombosis of 
cerebral vessels themselves or by emboli form a proximal arterial source or 
the heart. Cerebral hemorrhage produces neurological symptoms by 
producing a mass effect of neural structures or from the toxic effects of 
blood itself.  
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CEREBRAL BLOOD FLOW (68) 
 
 Gray matter – 75ml / 100gm / min  
 White matter – 30 ml / 100gm / min  
 Oxygen consumption – 3.5ml /100gm /min  
 Glucose utilization – 5 mg / 100 gm / min  
 
Brain store of glucose lasts only for 2 min after cessation of blood flow. 
The oxygen stores last only for 8 to 10 sec after cessation of blood flow.  
 
A fall in blood flow to zero causes death of brain tissue within 4 to 10 
min. Tissue surrounding the core region of infarction is ischemic but 
reversibly dysfunctional and is referred as the ischemic penumbra. The 
ischemic penumbra will eventually undergo infarction  if reperfusion is not 
achieved and hence saving the ischemic penumbra is the goal of 
thrombolytic therapy.  
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RISK FACTORS FOR STROKE 
Major risk factors (14):  
 The most important established risk factor for stroke is AGE, and 
second is probably HYPERTENSION. Additional well established risk 
factors are 
1. Gender (male > female)  7. Carotid bruits  
2. Family history  8. Smoking  
3. Diabetes mellitus  9. Increased haematocrit 
4. Cardiac disease  10. Elevated fibrinogen level  
5. Prior stroke  11. Haemoglobinopathy 
6. Transient Ischemic attacks  12. Drug abuse such as cocaine 
 
Other risk factors (15):  
1. hyperlipidemia  
2. Diet  
3. Oral contraceptives  
4. Sedentary life style  
5. Obesity  
6. Peripheral vascular disease  
7. Hyperuricemia 
8. Infections 
9. Homocystinemia 
10. Migraine  
11. Race 
12. Geographic location  
13. Season and climate  
14. Type A personality  
15. Alcohol consumption 
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Clinical presentation  
             Among all the neurologic diseases of adult life, stroke ranks first in 
frequency and importance. The common mode of expression of stroke is a 
relatively sudden occurrence of a focal neurologic deficit. Strokes are 
broadly categorized as ischemic or hemorrhagic. Ischemic stroke is due to 
occlusion of a cerebral blood vessel and causes cerebral infarction. The 
resultant neurologic syndrome corresponds to a portion of the brain that is 
supplied by one or more cerebral vessels.  
 Ischaemic and haemorrhagic stroke cannot be differentiated based on 
history. But haemorrhagic usually presents with features of increased 
intracranial tension ( nausea, vomiting, and headache). Seizures can occurin 
up to one-fourth of hemorrhagic strokes whereas it is not as common in 
ischaemic stroke. Symptoms of meningeal irritation can also occur due to 
bleeding into the ventricles after a haemorrhagic stroke and can mimic acute 
meningitis . Four types of stroke syndromes are commonly seen following 
involvement of certain vascular distributions.  
 
Anterior cerebral artery  
 
 ACA infarction usually presents with weakness on the contralateral 
side of the body predominantly involving the legs and, to a lesser extent, the 
arm. Such a pattern is usually seen when the hemispheric branches of ACA 
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are involved. The presentation of ACA infarction depends on the involved 
site  and collateral blood flow. Other features are lack of motivation, akinetic 
mutism in medial frontal lobe involvement, transcortical aphasia usually 
when the dominant lobe is involved, deviation of the head and eyes toward 
the side of the lesion, paratonia (involuntary variable resistance during 
passive movement), disturbances of memory and emotions, loss of 
proprioceptive sensation in the legs, and bladder disturbances ( due to 
paracentral lobule involvement). 
               Involvement  of the branches supplying corpus callosum leads to 
apraxia, agraphia, and tactile anomia of the left hand. The artery of Heubner 
supplies the  anterior limb of the internal capsule. Involvement of this artery 
can cause a pure motor weakness of the face and arm on the involved side. A 
Disconnection syndrome occurs when the communicating white fibres of the 
corpus callosum are involved and manifests as left ideomotor apraxia and 
left hand agraphia . Involvement of the inferior branches of ACA causes 
memory disturbances and behavioural abnormalities. 
 
Middle cerebral artery 
  
 The clinical presentation of  MCA territory infarct  depends on 
whether  the stem of the artery, superior branch, inferior branch, or 
lenticulostriate arteries are involved. Collateral circulation plays a major role 
in the presentation of a MCA stroke.  
18 
 
             An  MCA stem lesion and upper-division MCA infarction can be 
differentiated by the fact that the face and arm are more involved in the 
hemiparesis compared to the leg when the upper division is involved.  
Broaca’s ( motor ) aphasia occurs when of the anterior branches of the 
upper-division are occluded resulting in disturbances of blood flow in the 
inferior frontal lobe.              
            If the stem of the MCA is involved, it causes a large hemispheric 
infarction. It presents clinically as hemianesthesia,  homonymous 
hemianopia contralateral hemiplegia and horizontal deviation of the eyes 
ipsilaterally to the involved side. When the dominant hemisphere infarction 
occurs it causes global aphasia. Non-dominant lobe involvement presents as 
unilateral hemineglect. 
           When the lower-division of MCA is involved, a Wernicke’s (sensory) 
aphasia is seen when the dominant hemisphere undergoes infarction. 
Occlusion of  the lenticulostriate branches may cause a of pure motor 
hemiparesis. Such lacunar infarcts are common when  the internal capsule is 
involved.  Infarction of the nondominant lobe causes behavioural 
disturbances. Homonymous hemianopia can occur if the optic tracts are 
involved. 
             Gerstmann syndrome is characterized by right-left disorientation, 
finger agnosia, acalculia, and agraphia. It is usually seen when inferior 
parietal lobe (dominant) is affected. A contralateral  inferior quadrantanopia 
can occur when either hemisphere is involved. Alexia and agraphia can 
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occur with angular gyrus and supra-marginal gyrus involvement usually 
when the left side is involved. 
 
Posterior cerebral artery  
  
The clinical features of PCA infarct is based on the site of occlusion. (1) P1 
syndrome – when the proximal segment and its penetrating branches are 
involved (2) P2 syndrome – when the occlusion is distal to the site of joining 
of PCA with posterior communicating artery. P1 segment occlusion causes 
lesions in the midbrain, thalamus, and hemispheres . It mainly involves 
posterior choroidal and thalamogeniculate arteries. P2 segment occlusion 
causes temporal and occipital lobe infarction. 
             Involvement of the hemispheral branches causes contralateral 
homonymous hemianopia. It occurs because of the infarction of striate 
cortex,  optic radiation and the lateral geniculate body. A third nerve palsy 
with contralateral ataxia also known as Claude's syndrome can occur. If it is 
associated with contralateral hemiplegia then it is known as Weber's 
syndrome 
             The  Dejerine-Roussy syndrome occurring in thalamic infarction 
manifests as contralateral hemisensory loss and a severe burning pain in the 
affected areas. Bilateral proximal PCA occlusion causes extensive infarction 
of the midbrain and sub-thalamus leading to coma, unreactive pupils， 
bilateral pyramidal signs, and decerebrate rigidity.  
20 
 
             Most common visual changes are visual hallucinations, visual and 
color agnosias and prosopagnosia. Anton’s syndrome and Balint syndrome 
are seen in bilateral PCA infarcts. Ataxia and contralateral hemiballismus 
may also occur indicating involvement of red nucleus and subthalamic 
nucleus respectively.  
. 
Vertebrobasilar artery  
 
         The vertebral artery arising from the subclavian artery has four 
segments. The first segment extends from its origin to the sixth transverse 
vertebral foramen. The second segment extends from the C6 to C2 vertebral 
foramen. The third segment pierces the dura at the foramen magnum. The 
fourth  segment  joins the vertebral artery of the opposite side to form the 
basilar artery. The various manifestation depend on the segment involved.  
          Superior cerebellar artery involvement causes ipsilateral cerebellar 
ataxia, dysarthria and loss of pain and temperature sensation over the 
contralateral half of the body and face (spinothalamic and trigeminothalamic 
tract) . Horner's syndrome and palatal myoclonus are also observed. 
          PICA ( posterior inferior cerebellar artery ) involvement causes 
cerebellar infarctions. When the medial branch is involved the clinical signs 
and symptoms are vertigo, ataxia, and nystagmus due to dysfunction of  the 
vermis and vestibular system. When the lateral branch is involved it causes 
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vertigo, gait ataxia, limb ataxia, nausea, gaze palsies and dysarthria due to 
dysfunction of the cerebellar hemispheres. 
           The AICA (Anterior inferior cerebellar artery) occlusion causes 
ipsilateral deafness, facial weakness, tinnitus, vertigo and paresis of 
conjugate lateral gaze because of infarction of the vestibular nuclei present 
in the ventral portion of cerebellum. 
Locked-in syndrome is a state of preserved consciousness with  
quadriplegia, aphonia, and cranial nerve involvement due to bilateral pontine 
or midbrain infarction.  
            Lateral Medullary Syndrome ( Wallenberg syndrome ) can be caused 
by occlusion of the PICA. It is characterized by pain, numbness, and 
impaired sensation over the ipsilateral face, ipsilateral Horner’s syndrome, 
ipsilateral ataxia, dysphagia and loss of pain and temperature sensation in the 
contralateral half of the body.  
Massive infarctions involving the vertebro-basilar systems can cause 
altered consciousness or confusion by causing cytotoxic edema and 
brainstem compression. Hydrocephalus and brainstem herniation are rare 
and fatal complications. 
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The Major Causes of Cerebral Vascular Occlusion and Ischemic Stroke 
Two major causes of ischaemic stroke are: 
1.  atherosclerotic thrombotic disease of the cerebral or extracerebral 
vessels and 
2. cerebral embolism. 
Atherothrombosis : 
          The evolution of clinical phenomena in cerebral thrombosis, both of 
large intracranial (basilar, carotid) or extracranial (carotid, vertebral) and 
small vessels (lacunes), is more variable than that of embolism and 
hemorrhage. 
          The thrombotic stroke presents clinically in various ways. It may 
present completely at once or it may evolve over a period of time (minutes to 
hours). Such type of presentation is also called as a "stuttering" or evolving 
stroke. Rarely the thrombotic stroke may progress over a few days time. 
          Also characteristic of atherothrombotic events in many, but not all 
cases, is the occurrence of the stroke during sleep; the patient awakens 
paralyzed, either during the night or in the morning. Unaware of any 
difficulty, he may arise and fall helplessly to the floor with the first step. 
          Atheromatous plaques preferentially form at branching points and 
curves of the cerebral arteries. The most frequent sites are  
(1) in the internal carotid artery; at its origin from the common carotid; 
(2) in the cervical part of the vertebral arteries and at their junction to form 
the basilar artery;  
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 (3) in the stem or at the main bifurcation of the middle cerebral arteries; 
 (4) in the proximal posterior cerebral arteries as they wind around the 
midbrain;  
(5) in the proximal anterior cerebral arteries as they pass anteriorly and curve 
over the corpus callosum. 
                The last two sites are far less frequent than the first three. 
                Atherothrombosis may cause cerebral infarction in several ways. 
The most obvious is that an occlusive plaque or a thrombus formed on a 
plaque occupies the lumen of a major intracerebral vessel, such as the 
middle cerebral artery, and stops flow to the areas of the brain supplied by 
the vessel.  
                 A variation of this mechanism is one of occlusion by 
atherosclerosis of a more proximal vessel, such as the distal carotid artery. 
This leads to infarction in the territory between major branches of the 
internal carotid circulation that are most susceptible to reduced blood flow-
termed "watershed infarction." 
               Or, an atherothrombotic lesion in a proximal vessel  may  serve as 
the nidus for the formation of an embolus that manifests itself as a stroke in 
one of the territories of that vessel-called "artery-to-artery" embolism. 
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Cerebral Embolism 
 
         This is the most common cause of ischemic strokes Although the 
abruptness with which the stroke develops and the lack of prodromal 
symptoms point strongly to embolism, the diagnosis is based on the total 
clinical circumstances. Embolism always merits careful consideration in 
young persons, in whom atherosclerosis is less common. Only occasionally 
does the problem unfold more gradually, over many hours, with some 
fluctuation of symptoms. Possibly, in these cases the embolus initiates a 
propagating thrombotic process in the occluded vessel. 
                 In most cases, the embolic material consists of a fragment that has 
broken away from a thrombus within the heart ("cardioembolic"). Somewhat 
less frequently, the source is intra-arterial from the distal end of a thrombus 
within the lumen of an occluded or severely stenotic carotid or vertebral 
artery, or a clot that originates in the systemic venous system and passes 
through an aperture in the heart walls, or the origin of an embolus may be 
from large atheromatous plaques in the aorta.  
               Thrombotic or infected material (endocarditis) that adheres to the 
aortic or mitral heart valves and breaks free are also well-appreciated sources 
of embolism, as are clots originating on prosthetic heart valves. Embolism 
caused by fat, tumor cells (atrial myxoma), fibrocartilage, amniotic fluid, or 
air enters into the differential diagnosis of stroke only in special 
circumstances 
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               The embolus usually becomes arrested at a bifurcation or other site 
of natural narrowing of the lumen of an intracranial vessel. The resultant 
infarction is pale, hemorrhagic, or mixed; hemorrhagic infarction nearly 
always indicates embolism (although venous occlusion can do the same).           
Any region of the brain may be affected, the territories of the middle 
cerebral artery, particularly the superior division, being most frequently 
involved. The two cerebral hemispheres are approximately equally affected. 
                Large embolic clots can block large vessels (e.g., the carotid 
arteries in the neck or at their termination intracranially), while tiny 
fragments may reach vessels as small as 0.2 mm in diameter, usually with 
inconsequential effects. The embolic material may remain arrested and plug 
the lumen solidly, but more often it breaks into fragments that enter smaller 
vessels so that even careful pathologic examination fails to reveal their final 
location. In this instance, the clinical effects may abate. Because of the 
rapidity with which embolic occlusion develops, useful collateral influx does 
not become established. Thus, sparing of the brain territory distal to the site 
of occlusion is usually not as evident as in thrombosis that develops more 
slowly. 
                   Several scoring systems have been developed to gauge the future 
likelihood of stroke from atrial fibrillation. The CHADS2 and related 
systems are shorthand methods to quantitate the risk factors that modulate 
risk for stroke in a patient with atrial fibrillation. A refinement of this 
system, CHADS2-VASc is purported to improve these predictions but the 
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confidence intervals around the point estimates of predictive values in both 
scales are considerable and clinical judgment must be exercised in their use. 
              Another source of embolism is the carotid or vertebral artery, where 
clot forming on an ulcerated atheromatous plaque may be detached and 
carried to an intracranial branch (artery-to-artery embolism). 
              Atheromatous plaques in the ascending aorta have been recognized  
to be a more frequent source of embolism than had been previously 
appreciated. Amarenco and colleagues reported that as many as 38 percent 
of a group of patients with no discernible cause for embolic stroke had 
echogenic atherosclerotic plaques in the aortic arch that were greater than 4 
mm in thickness, a size found to be associated on a statistical basis with 
strokes. 
              The migrating or traveling embolus syndrome is most evident in 
cases of posterior cerebral artery occlusion, either from a cardiogenic  source 
or from a thrombus in the proximal vertebral artery ("artery-to-artery" 
embolism). Minutes or more before the hemianopia develops, the patient 
reports fleeting dizziness or vertigo, diplopia, or dysarthria, the result of 
transient occlusion of the origins of penetrating vessels as the clot material 
traverses the basilar artery. 
                Paradoxical embolism occurs when an abnormal communication 
exists between the right and left sides of the heart (particularly a patent 
foramen ovale [PFO]) or the alternative route of connection via a pulmonary 
arteriovenous fistula. Embolic material arising in the veins of the lower 
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extremities or pelvis or elsewhere in the systemic venous circulation 
bypasses the pulmonary circulation and reaches the cerebral vessels. 
Pulmonary hypertension (often from previous pulmonary embolism) favors 
the occurrence of paradoxic embolism, but these strokes occur even in the 
absence of pulmonary hypertension. 
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PATHOPHYSIOLOGY OF STROKE (1) 
 
Cerebral infarction basically comprises two pathophysiologic processes.  
1. Loss in the oxygen delivery and nutrient supply due to vascular 
occlusion.  
2. Alterations in the metabolic processes within the neurons resulting in 
cell death. 
Vascular Factors: 
 In several animal species including macaque monkeys and gerbils the 
critical level of cerebral blood flow was 23ml / 100gm / min; if, after short 
periods time, CBF is restored to higher levels the impairment of function can 
be reversed. Reduction of CBF below 10 to 12 ml / 100 gm / min causes 
infarction regardless of duration. The critical level of hypoperfusion that 
abolishes function and leads to tissue damage is therefore a CBF between 12 
to 23 ml / 100gm / min. At this level EEG is slowed and below this level it 
becomes isoelectric. These biochemical abnormalities are reversed if the 
circulation is restored to normal level. Disturbance of calcium ion 
homeostasis and accumulation of free fatty acids interfere with full recovery. 
A CBF of 6 to 8 ml / 100 gm / min causes marked ATP depletion, increase 
in extra cellular K+, increase in intracellular calcium and cellular acidosis, 
leading invariably to histological signs of necrosis. Free fatty acids are 
activated and destroy the phospholipids of neuronal membranes. 
29 
 
Prostaglandins, leukotrienes and free radicals accumulate and intracellular 
proteins and enzymes are denatured.  
 Penumbra zone exists at the margin of an infarction  and the degree of 
irreversible tissue damage is difficult to determine. The neurons in this zone 
is considered to be “stunned” by  ischemia and this tissue is potentially 
recoverable if appropriate interventions are undertaken to restore blood flow. 
As with infarction, the duration of ischemia plays a role. Some studies show 
that maintaining the systolic BP or modifying the rheological flow of blood 
within the vascular system by haemodilution alters the perfusion in a 
desirable manner  
 
Metabolic Factors: 
 Focal cerebral infarction occurs via two ways  
( 1 )  a necrotic pathway in which cellular cytoskeletal breakdown is 
        rapid due principally to energy failure of the cell 
 (2)  an apoptotic  pathway in which cells become programmed to die. 
                   Ischemia produces necrosis by starving neurons of glucose and 
oxygen， which in turn results in failure of mitochondria to produce ATP. 
 Without ATP, membrane ion pumps stop functioning and neurons 
depolarize，allowing intraιellular calcium to rise. Cellular depolarization 
also causes glutamate release from synaptic terminals; excess extracellular 
glutamate produces neurotoxicity by activating postsynaptic glutamate 
receptors that increase neuronal calcium influx.  
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           Free radicals are produced by degradation of membrane lipids and 
mitochondrial dysfunction. Free radicals cause catalytic destruction of 
membranes and likely damage other vital functions of cells. Lesser degrees 
of ischemia， as are seen within the ischemic penumbra, favor apoptotic 
cellular death causing cells to die days to weeks later.  
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Neuroimaging in Stroke: 
     Plain CT Brain is done for all patients presenting with stroke to 
differentiate between ischaemic and hemorrhagic stroke. It is also useful to 
rule out intracranial mass lesions or neoplasms that can present with 
neurological deficits and masquerade as a stroke. When involvement of the 
posterior circulation is suspected in cases presenting with brainstem and 
cerebellar symptoms, CT should include fine cuts through the posterior 
fossa. 
                MRI is better than CT in detecting cerebral vascular diseases. MRI 
is superior particularly in cases involving the posterior circulation and 
lacunar infarcts. Another notable advantage is that MRI can rapidly detect 
the “ischemic penumbra” and guide decisions regarding therapeutic 
intervention. 
                 The tissue water content is very useful to differentiate infarction 
from other lesions. Diffusion weighted images help in differentiating 
between acute and chronic stroke.  
 
Features of an Early Stroke in CT Scan: 
 Loss of gray/white-matter differentiation ( insular-ribbon sign)   
 Dense  MCA sign ( the horizontal part of MCA appears dense) 
 Obscuration of the lentiform nucleus,   
 Effacement of the sylvian fissure 
 Midline shift because of cerebral oedema 
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Fig 1: CT scan showing insular ribbon sign 
Black arrow shows the loss of grey/white matter differentiation at the insula 
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                 Fig 2: CT scan showing hyperdense MCA sign 
White arrow shows the hyperdense horizontal portion of middle cerebral 
artery 
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Fig.3 CT scan showing obscuration of lenticular nucleus 
 
The filled black arrows show the ill-defined borders of the lenticular 
nucleus  
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SUA AND PATHOGENESIS OF STROKE 
 
 The mechanism by which uric acid causes stroke could be explained 
by experimental evidences. The possible mechanisms are as under.  
 
SUA AND HYPERTENSION: 
 
1. Increased SUA level precedes hypertension in one-fourth of newly 
diagnosed hypertension cases (21).  
2. Hypertension leads to low renal perfusion which in turn causes uric acid 
reabsorption thereby leading to hyperuricemia (22).  
3. Increased uric acid levels also caused elevated blood pressure in rats by 
a  mechanism linked to inhibition of nitric oxide (NO), activation of 
rennin – angiotensin system, and development of renal arteriosclerosis 
(23). Once the renal arteriosclerosis develops, the kidney plays a major 
role in the maintenance of hypertension, and lowering the UA is no 
longer protective (24). 
4. High uric acid level in rats cause kidney damage by mechanisms other 
than crystal deposition (23) and worsen pre-existing kidney damage 
(25).  
5. UA also increases the production of cytokines like monocyte 
chemoattractant protein – 1 (MCP-1) from smooth muscle cells in the 
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blood vessels (26) and is  a precursor for chemotaxis and inflammation 
in the blood vessels leading to atherosclerosis (27).  
 
SUA AND FREE  RADICAL MEDIATED OXIDATIVE DAMAGE – 
CEREBRAL ISCHEMIA 
 
1. Cerebral infarction leads to multiple pathogenic processes in the 
surrounding tissue and free – radical – mediated oxidative damage plays 
a key role in the pathogenesis of cerebral ischemia (28). Free radicals 
are liberated from a variety of sources, including inflammatory cells, 
dysfunctional mitochondria and excitotoxic mechanisms stimulated by 
increased glutamate and aspartate concentrations (29).  
2. Hydroxyl radicals, peroxy-nitrite and superoxide, are free radicals that 
can cause lipid peroxidation, a self – propagating chain reaction that 
irreversibly damages plasma and mitochondrial membranes (30). 
Products of lipid peroxidation irreversibly disrupt enzymes, receptors, 
and membrane transport mechanisms. The generation of local oxidants 
augments local injury and increases infarct size (28).  
3. UA is the most abundant aqueous antioxidant in humans and may serve 
a protective physiologic role by preventing lipid peroxidation (34). It 
might therefore be expected that having elevated SUA levels during a 
stroke would be beneficial. Stroke is associated with a rapid decrease in 
serum antioxidants (31,32) and patients with lower plasma antioxidants 
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at the time of acute stroke have a poorer outcome (33). However, only 
one study has reported that high SUA levels may be neuroprotective in 
patients with acute stroke (35), three other large series found the 
opposite (6,7,9).  
 
A probable explanation for this is that UA which usually functions as an  
aqueous antioxidant becomes pro-oxidant in conditions where other 
antioxidants like ascorbic acid are reduced (36). So a fall in ascorbic acid 
levels can cause SUA to become a pro-oxidant in patients affected by stroke. 
This hypothesis is proved by the observation that poor prognosis is observed 
in stroke patients with high SUA and low ascorbic acid levels (37).  
 
 
SUA AND ENDOTHELIAL DYSFUNCTION: 
 
 Experimental research provides evidence that hyperuricemia causes 
endothelial dysfunction leading to atherosclerosis. UA was found to cause 
endothelial dysfunction  when it was experimentally injected directly into 
the blood vessels(38). UA also caused oxidation of low density lipoproteins 
(39) and promoted neutrophil chemotaxis around blood vessels  (40).  
 Moreover elevation of circulating pro-inflammatory markers have 
also been related to increased SUA levels (41-43).  UA also accumulates as 
crystals in the atherosclerotic plaques (44).  
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SUA AND METABOLIC SYNDROME (MET S): 
 
 SUA also increases the risk of stroke by its relationship with Met S 
(45,46). SUA levels are consistently high in patients with Met S (47-49).  
1. Hyperuricemia and Met S both have a common underlying 
mechanism which is the Insulin Resistance (IR). It is closely 
associated with increased  SUA levels (45,50).  
2. Insulin – induced UA excretion is defective in patients with MetS. 
This could be a cause for elevated UA levels (45).  
3. Insulin Resistance also increases purine synthesis and turnover 
thereby causing elevated UA levels (45,50).  
4. SUA adversely affects endothelial function by inhibiting nitric oxide 
synthesis (38). Nitric Oxide is necessary for insulin mediated glucose 
uptake. So hyperuricemia indirectly causes IR (51).  
5. Recent studies have shown a significant association between 
hyperuricemia and the risk factors of Met S (48,52). Met S itself is an 
independent risk factor for cerebro vascular accidents (53-56).  
6. Elevated SUA levels has a prognostic value independent of all the 
other entities of Met S, showing a positive correlation  between SUA 
levels and poor prognosis in stroke (57).  
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REDUCTION OF SUA AND PROTECTION AGAINST STROKE: 
 
 Beyond  xanthine oxidase inhibitors like allopurinol and other 
uricosuric drugs (probenecid, sulfinpyrazone), some drugs like losartan and 
fenofibrate can decrease the SUA level(58). 
             Statins markedly reduce SUA levels (59) and protects kidney 
functions (60) and these effects independently augment their protection from 
vascular events  (49).  
            Thus reduction of SUA  could also adds to the beneficial effects of 
statins against cerebrovascular accident (61).  
 The findings of LIFE study (Losartan Intervention for Endpoint 
Reduction in hypertension study) suggest that losartan causes a fall in SUA 
and confers protection against stroke (8).  
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AIMS OF THE STUDY 
  
           The study is conducted to study the association between Serum Uric 
Acid (SUA) and acute ischaemic nonembolic stroke and to assess its risk 
factor potential using statistical analysis.  
 
 To also study the association between Serum Uric Acid (SUA) and 
other risk factors namely hypertension, Diabetes mellitus, CAD and adverse 
lipid profile.  
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MATERIALS AND METHODS 
 
Inclusion criteria: 
1. Patients who were admitted in our hospital with first – ever – in life 
time acute ischaemic nonembolic stroke with or without CT scan 
evidence of infarction within 24hrs of onset of stroke.  
 
Exclusion criteria:  
1. Patients with previous history of TIA /CVA 
2. Patients who are on thiazide diuretics  
3. Patients who are known cases of gout or show clinical evidences of 
gout.  
4. Patients with chronic renal failure  
5. Patients whose CT scan showing haemorrhage or other space 
occupying lesions other than infarct.  
6. Patients who were of known cardiac diseases which could be sources 
of emboli or whose echocardiogram shown sources of emboli.  
7. Patients with haemotological abnormalities like leukemia or other 
myeloproliferative disorders.  
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    A total of 100 patients (49 males and 51 females) with acute stroke 
who met the criteria, admitted in TMCH Thanjavur from 01.06.2014 to 
31.05.2015 were randomly selected and included in this study.  
 All subjects gave informed consent and the study protocol was 
approved by the Ethical Committee. 
 The blood samples were taken within 24hrs of onset of stroke and 
sent for biochemical analysis and were analyzed in our Biochemical 
Laboratory using standard analyzer. The patients were further evaluated for 
the presence of additional risk factors as follows, using the below mentioned 
parameters.  
 
1. HYPERTENSION:  
a) Known case of hypertension  
b) Blood pressure more than 140mm of Hg systolic and / or more than 
90mm of Hg diastolic (62)  
2. DIABETES MELLITUS: 
a) Known case of diabetes mellitus  
b) Random or postprandial blood sugar more than 200mgs / dl and / or 
fasting blood sugar more than 126mgs / dl (63)  
c) The patients with blood sugar values of IFG or IGT were not included 
as diabetics in this study.  
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3) CORONARY ARTERY DISEASE:  
 Patients with ECG evidence of old infarction or Echocardiogram 
showing regional wall motion abnormalities.  
 
4. ADVERSE LIPID PROFILE (64):  
 Total cholesterol  - more than 200mgs/dl  
 Triglycerides  - more than 150mgs / dl  
 LDL – C   - more than 130mgs/dl  
 HDL – C   - less than 40mgs / dl  
 
5. SMOKING AND ALCOHOLISM: 
 History of smoking and alcoholism within the last 5 years have been 
taken as smokers and alcoholics.  
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Statistical Tools  
 
          The information collected throughout the study period  was recorded 
in a Master Chart.. Data analysis was done with the help of a computer using 
Statistical Package for Social Sciences software (SPSS version 22).  
 Using this software, frequencies, percentage, mean, standard 
deviation, x2 and ‘p’ values were calculated. A ‘p’ value less than 0.05 is 
taken to denote significant relationship.  
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OBSERVATIONS AND RESULTS  
 The observations made in this study are categorized, analyzed and 
tabulated as under: 
 
1. AGE DISTRIBUTION: 
 In this prospective study, 41 to 83 yrs old patients are included.  
 
Table 1.1: Age Distribution 
Age in years  Cases 
No  %  
Less than 40 - - 
41-50 21 21 
51-60 30 30 
61-70 33 33 
71 yrs & above 16 16 
Total  100 100 
Mean  
S.D  
59.84 yrs 
10.47 
 
Above 71 yrs old constitute 16% of the population with 8 males and 8 
females. 
 
50 
 
 
Figure 1  
AGE DISTRIBUTION 
 
 
 
 People aged 41-50 constitute 21% of the study population with 10 
males and 11 females  
 People aged over 60 ( elderly ) constitute 49% of the population  
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Table 1.2: Age Distribution according to sex 
 
Age in years  Cases  
Males  Females  
No.  %  No.  % 
Less than 40 - - - - 
41-50 10 20.4 11 21.6 
51-60 21 42.9 9 17.6 
61-70 10 20.4 23 45.1 
71 & above 8 16.3 8 15.7 
     
Total 49 100 51 100 
Mean 
S.D 
59.1 
10.2 
60.5 
11.1 
‘p’ 0.238 
Not significant 
 
 The mean age of the male population is 59.1 yrs and of the female 
population is 60.5 yrs. The overall mean age of the study population is 
59.84yrs.  
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2. RISK FACTORS:  
 
Table 2.1: Risk Factors  
Risk Factor  Cases  
No  %  
a) Hypertension  
Present  
Absent  
 
66 
34 
 
66 
34 
b) DM  
Present  
Absent  
 
52 
48 
 
52 
48 
c) Smoking  
Present  
Absent  
 
34 
66 
 
34 
66 
d) CAD  
Present  
Absent  
 
33 
67 
 
33 
67 
e) Dyslipidemia 
Present  
Absent  
 
34 
66 
 
34 
66 
f) Alcoholism  
 
Alcoholic  
Non alcoholic  
 
 
 
20 
80 
 
 
 
20 
80 
 
 
      Hypertension is the most common risk factor found in this study 
population. 
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 Hypertension constitutes the major risk factor in this stroke 
population as 66% of the population is hypertensive. 33 males and 
females are hypertensives and form 67% and 64% in their respective 
population. 
 Diabetes mellitus ranks second as a risk factor, constitute 52% of the 
study population with 29 (59%) males and 23 (45%) females.  
 Coronary Artery Disease is associated in 33% of the population with 
14 (28%) males 19 (37%) females.  
 34% of the stroke population has adverse lipid profile and both sexes 
share equal number of patients with abnormal lipid profile (17 each).  
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Table 2.2: Risk Factors according to sex 
 
 
Risk Factor  
Cases  
Males  Females  
No.  %  No.  %  
a) Hypertension  
Present  
Absent  
 
33 
16 
 
67.3 
32.7 
 
33 
18 
 
64.7 
35.3 
b) DM 
Present  
Absent  
 
29 
20 
 
59.2 
40.8 
 
23 
28 
 
45.1 
54.9 
c) Smoking  
Present  
Absent  
 
34 
16 
 
68 
32 
 
- 
50 
 
- 
100 
d) CAD 
Present  
Absent  
 
14 
35 
 
28.6 
71.4 
 
19 
32 
 
37.3 
62.7 
e) Dyslipidemia 
Present  
Absent  
 
17 
32 
 
34.7 
65.3 
 
17 
34 
 
33.3 
66.7 
f) Alcoholism  
 
Alcoholic  
Non Alcoholic  
 
 
 
18 
31 
 
 
 
36.7 
63.3 
 
 
 
2 
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3.9 
96.1 
 
 
 Among the male population, 34 (68%) are smokers and 18 (36%) are 
alcoholics.  
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FIG: 3  URIC ACID DISTRIBUTION 
 
 
 
 
 
 Uric acid levels above and equal to 7mg / dl – 25% (12 males and 13 
females)  
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3.Uric acid levels and their association with risk factors:  
 
 The distribution of uric acid levels in the study population are as 
under:  
 Less than 5mg / dl – 48% (25 males and 23 females)  
 Between 5 – 6.9 mg / dl – 27% (12 males and 15 females)  
 Above and equal to 7mg / dl – 25% (12 males and 13 females)  
 
 
Table 3.A. : Uric Acid (mg/dl)  
Uric Acid 
(mg/dl) 
Cases 
Males Females 
No. % No. % 
Less than 5 25 51 23 45.1 
5-6.9 12 24.5 15 29.4 
7 & Above  12 24.5 13 25.5 
Total  49 100 51 100 
Mean  
S.D  
5.390 
1.89 
5.513 
1.50 
‘p’ 0.736 
Not significant 
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FIG 3.1.1 
AGE AND URIC ACID LEVELS 
 
 
 
Mean uric acid level in males is 5.39mg /dl and in females it is 5.51 mg/dl. 
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3.1. AGE AND URIC ACID:  
 
Table 3.1.1: Age and uric acid 
Age group  Uric Acid  
mg/dl 
Mean  S.D 
41-50 4.342 1.16 
51-60 5.076 1.44 
61-70 5.930 1.67 
70& above 6.656 1.81 
‘p’ 0.0001 (Significant)  
 
 Age wise distribution of uric acid is found statistically significant. As 
age advances the uric acid level also rises with the ‘P’ value of 0.0001. This 
significance is maintained even when male and female populations are 
considered separately. (‘P’ of 0.0056 for males and 0.0077 for females). 
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Table 3.1.2: Age and uric acid according to sex 
 
Age group  Uric Acid  
Males Females 
Mean  S.D Mean  S.D 
41-50 4.21 1.54 4.46 0.71 
51-60 5.05 1.50 5.12 1.38 
61-70 5.92 2.03 5.93 1.53 
71 & above 7.12 1.92 6.18 1.68 
‘p’ 0.0056 
Significant  
0.0077 
Significant 
 
  
The mean uric acid value for 40-49 yrs group is 4.34 mg/dl while the elderly 
age group of above 70 yrs has the mean value 6.65 mg/dl. 
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3.2: SEX AND URIC ACID: 
 
 
Table 3.2.1: Sex and uric acid level 
Sex  Uric acid (mg/dl) 
Mean  S.D 
Males  5.39 1.89 
Females  5.51 1.50 
‘p’ 0.736 (Not significant)  
 
 
There is no statistically significant association found in this study 
between sex and uric acid. The mean uric acid level among male population 
is 5.39mg/dl and among female population it is 5.51 mg/dl.  
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3.3: HYPERTENSION AND URIC ACID:  
 
 
Table 3.3.1: Hypertension and uric acid 
Hypertension  
 
Uric acid (mg/dl) 
Mean  S.D 
Present  5.66 1.66 
Absent  5.07 1.68 
‘p’ 0.756 (Not significant) 
 
 
This study does not show any significant association between 
hypertension and uric acid. The mean uric acid level in hypertensive 
population is 5.66 mg/dl and in non hypertensive population is 5.07 mg/dl.  
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Table 3.3.2: Hypertension and uric acid – sex wise 
 
 
Hypertension  Uric acid (mg/dl) 
Males   Females   
Mean  S.D Mean  S.D 
Present  5.45 1.78 5.86 1.55 
Absent  5.27 2.17 4.87 1.20 
‘p’ 0.370 
Not significant 
0.023 
Significant 
 
 
There is a significant association found, also when males and females 
are considered separately. The mean uric acid levels for male hypertensives 
is 5.45 mg/dl (non hypertensive males 5.27mg/dl) and in females is 5.86 
mg/dl (non hypertensive females – 4.87 mg/dl). So hypertensive females 
have a higher incidence of hyperuricemia. 
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Figure 3.4 
DIABETES MELLITUS AND URIC ACID 
 
 
 
Among diabetics the mean uric acid is 6.10 mg/dl while among non 
diabetics it is 4.86 mg/ dl. 
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3.4: DIABETES MELLITUS AND URIC ACID:  
 
 
Table 3.4.1: DM and uric acid 
DM  Uric Acid (mg/dl)  
Mean  S.D 
Present  6.10 1.62 
Absent  4.86 1.56 
‘p’ 0.0006 (Significant)  
 
 
There is a statistically significant association (p value – 0.0006) found 
between the level of uric acid and Diabetes mellitus. Among diabetics the 
mean uric acid is 6.10 mg/dl while among non diabetics it is 4.86 mg/ dl.  
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Table 3.4.2: DM and uric acid according to sex  
 
DM    Uric Acid (mg/dl)  
                    Male                                           Female 
Mean  S.D  Mean  S.D  
Present  6.35 1.89 5.91 1.42 
Absent  4.73 1.62 5.02 1.49 
‘p’ 0.002 
Significant  
0.033 
Significant 
 
 
This association is more significant among males (p value – 0.002) 
among whom the diabetics have 6.35 mg/dl as mean uric acid level 
compared to non diabetics, 4.73 mg/dl as mean value.  
 
This association is also found significant in female population. The 
mean uric acid level in diabetic women is 5.91 mg/dl when compared to non 
diabetic women is 5.02 mg/dl.  
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Fig 3.5.1 
CAD AND URIC ACID LEVELS 
 
 
 
                    Mean uric acid level in this stroke population with CAD is 6.37 
mgs/dl and in those without CAD is 5.00 mgs/dl 
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3.5: CAD and Uric acid:  
 
Table 3.5.1: CAD and Uric acid  
 
CAD  Uric Acid (mg/dl)  
Mean  S.D 
Present  6.37 1.88 
Absent  5.00 1.41 
‘p’ 0.0004 (significant) 
 
  
             In this study, mean uric acid level in this stroke population with 
CAD is 6.37 mgs/dl and in those without CAD is 5.00 mgs/dl and thus 
establishes a statistically significant relationship (‘p’ 0.0004).  
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Table 3.5.2: CAD and Uric acid according to sex  
 
 
CAD  Uric Acid (mg/dl)  
Males  Females  
Mean  S.D Mean  S.D  
Present  7.02 1.80 5.90 1.84 
Absent  4.74 1.52 5.28 1.24 
‘p’ 0.0003 
Significant  
0.1559 
Not significant 
 
  
When males and females are considered, males have a significant 
association with a ‘p’ values of 0.0003. Female population does not show 
such association. (See table)  
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3.6: Hyperlipidemia and uric acid: 
 
Table 3.6.1: Hyperlipidemia and Uric acid 
 
Hyperlipidemia  Uric Acid (mg/dl)  
Mean  S.D 
Present  5.76 1.89 
Absent  5.29 1.58 
‘p’ 0.260 (Not significant)  
 
 
Mean uric acid level in hyperlipidemic stroke population is 5.76 
mgs/dl and compared to 5.29 mgs / dl mean uric acid level in patients 
without hyperlipidemia do not show any statistical significance. 
 
 
 
 
 
 
70 
 
 
 
 
Table 3.6.2: Hyperlipidemia and Uric acid according to sex  
 
 
Hyperlipidemia Uric Acid (mg/dl) 
Males Females 
Mean S.D Mean S.D 
Present  5.68 2.16 5.85 1.64 
Absent  5.24 1.76 5.34 1.42 
‘p’  0.451 
Not significant 
0.260 
Not significant  
 
 
There is no statistically significant relationship even when males and 
females are analysed separately.  
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3.7: Smoking and uric acid:  
 
 
Table 3.7.1: Smoking and Uric acid 
Smoking  Uric Acid (mg/dl)  
Mean  S.D  
Present  5.16 1.80 
Absent  5.60 1.64 
‘p’  0.215 
Not significant 
 
 
                   Mean uric acid level in smokers is 5.16mg / dl and among non-
smokers is 5.60 mgs /dl. Thus in this study there is no statistically significant 
relationship between smoking and uric acid. 
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4. RISK FACTORS IN POPULATION WITH HIGH URIC ACID 
LEVEL (ie..>7mgs / dl) 
 
Table 4.1 : Risk factors and uric acid levels </> 7 mgs / dl 
Risk Factors Uric acid 
< 7mg/dl > 7mg/dl 
No. % No. % 
a) Hypertension 
Present 
Absent 
 
46 
29 
 
61 
39 
 
20 
5 
 
80 
20 
‘P’ 0.108    
Not significant 
b) DM 
Present 
Absent 
 
44 
31 
 
59 
41 
 
8 
17 
 
32 
68 
‘P’ 0.001 
Significant 
c)Smoking  
 
Present 
Absent 
 
 
27 
48 
 
 
        36 
        64 
 
 
7 
18 
 
 
        28 
        72 
‘P’ 0.523 
Not significant 
d) CAD 
Present 
Absent 
 
16 
59 
 
21 
79 
 
17 
8 
 
68 
32 
‘P’ 0.0001 
Significant 
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Risk Factors Uric acid 
< 7mg/dl > 7mg/dl 
No. % No. % 
e) Dyslipidemia 
Present 
Absent 
 
22 
53 
 
29.3 
70.7 
 
12 
13 
 
48 
52 
‘P’ 0.145 
Not significant 
f) Alcoholism 
(among males) 
Alcoholic 
Non Alcoholic  
 
 
14 
61 
 
 
18.6 
81.3 
 
 
6 
19 
 
 
24 
         76 
‘P’ 0.696 
Not significant 
No risk factor  
At least one risk 
factor 
7 
68 
9.3 
90.7 
2 
23 
8 
92 
‘P’ 0.6008 
Not significant 
Age  
>65 
<65 
 
11 
64 
 
42.3 
86.5 
 
15 
10 
 
57.7 
13.5 
‘p’ 0.0001 
Significant 
 
Further analysis is done to analyse the relationship between uric acid 
levels less than and more than 7mgs/dl and the risk factors. This analysis 
shows age more than 65 yrs, Diabetes mellitus and CAD have statistically 
significant relationship with uric acid level.  
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DISCUSSION 
 
 In this prospective study of 100 stroke patients, males and females are 
almost equal in number  and hence there is no sex bias. Further analysis 
shows the mean age, (males – 59.1yrs, females 60.5yrs) and mean level of 
uric acid (males – 5.39mgs/ dl, females – 5.51mgs / dl) are similar. 
Distribution of risk factors also is of in more or less similar pattern 
(Hypertension: males – 33, females – 33; Diabetes mellitus: males – 29, 
females 23; CAD: males – 14 females – 19; Hyperlipidemia; males – 17, 
females – 17). Different studies (9, 12) show high mean uric acid level in the 
study population which is not found in this study.  
 But, in elderly population, both sexes show high level of uric acid 
which has statistical significance. Regarding the association between risk 
factors and both sexes, CAD is significantly associated with high uric acid 
levels in both sexes whereas DM is also associated with high uric acid levels 
in both sexes.  
 In this study, most of the population belongs to anterior circulation 
territory, especially of middle cerebral artery region with commonest 
presentation being hemiplegia, except in two patients with  cerebellar 
infarction evidenced in MRI scan. As most of the posterior circulation 
strokes have masquerading clinical presentations and often lack CT scan 
evidences of infarction, they are not included in this study to avoid inclusion 
bias.  
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 Age is the most common non-modifiable risk factor for the 
development of stroke (14). In this study, 16% of the populations are above 
71yrs with 8 males and 8 females. One pilot study (9) of 163 patients above 
70yrs studied the association of SUA and stroke and concludes that SUA is 
associated with an increased risk for acute ischaemic / nonembolicstroke in 
elderly patients independent of concurrent metabolic derangements. This 
study also shows evidences for a significant association between SUA and 
stroke in the elderly population, and the association was maintained even 
when both sexes are considered separately. Thus this study supports the 
association of high SUA and acute ischaemic / nonembolic stroke.  
 Hypertension is the most common modifiable risk factor for stroke 
(14). SUA is also commonly associated with hypertension (65,66). Elevated 
SUA level is an independent predictor of hypertension in 25% of patients 
with new onset, untreated primary hypertension (21). In this study, 
Hypertension constitutes the major risk factor as 66% of the stroke 
population is hypertensive. The mean uric acid level of hypertensive 
population is 5.66 mgs/dl and of non hypertensives 5.07 mgs/ dl and thus 
this study does not show any statistically significant relationship between 
SUA and hypertension.  
 
 
 
76 
 
 
 
 Diabetes mellitus ranks second as a risk factor in this study, constitute 
52% of the study population. One population based study (6) involving 1017 
person with NIDDM, concludes that hyperuricemia is a strong predictor of 
stroke events in middle aged persons with NIDDM, independent of other CV 
risk factors. SUA levels are often increased in subjects with MetS (47-49). In 
this study, with the mean SUA level of 6.10mgs/dl among diabetics and 
4.86mgs/dl among non-diabetics there is a strong association between SUA 
and DM. Further analysis shows this association is more stronger among 
males (mean SUA in male diabetics – 6.35 mgs/dl vs non-diabetic males – 
4.73 mgs/dl) than females. Thus this study strongly favours for an 
association between SUA and acute ischaemic/ nonembolic stroke in 
diabetic population.  
 
 SUA is significantly associated with cardiovascular mortality in 
certain epidemiological studies (13). One population based cohort study 
(67), with a follow up of 8.4yrs, comprising 4385 participants of the 
Rotterdam study concludes that SUA is a strong risk factor for myocardial 
infarction and stroke. In this study CAD is found in 33% of the patients with 
14 males and 19 females. The mean SUA level in this CAD population is 
6.37mgs /dl comparing this to patients without CAD is 5.00mgs/dl which 
shows a strong statistical significance. Among those 33 stroke patients with 
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CAD 17 have SUA >7mgs/dl. This also shows a strong statistical 
significance with a ‘p’ value of 0.0001. Hence this study strongly favours 
Rotterdam study and suggests SUA is a strong risk factor for myocardial 
infarction and stroke.  
  
          Several prospective studies (69,70) have shown that higher levels of 
total cholesterol increase the risk of ischaemic stroke. Furthermore a meta-
analysis of 90000 patients (61) showed that administration of statins reduces 
the risk of stroke among patients with CAD and that this risk reduction is 
primarily related to the extent to which LDL – C levels are lowered. In some 
studies (71.72) relating Met S and SUA, increased SUA levels correlated 
with low HDL – C levels.  
 
 In our study, Hyperlipidemia is considered separately and not as a 
part of Met S. Moreover, most of our patients in this study population are 
from low socio-economic group and are not found obese. In this study, the 
mean uric acid level hyperlipidemic patients is 5.76mgs / dl and in patients 
without hyperlipidemia is 5.29mgs/dl and does not show any significant 
association between these variables. Out of 34 patients with hyperlipidemia 
in this study, only 12 are found to have SUA > 7mgs /dl.  
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Among the other risk factors like smoking and alcoholism, they are 
not considered as separate risk factors in many pilot studies of this kind. This 
study also fails to show any statistically significant relationship between 
SUA and these risk factors when considered separately.  
  
            Further analysis between < 7mgs /dl and > 7mgs / dl SUA groups 
also maintain the association between high SUA and the risk factors namely 
age and CAD.  
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CONCLUSION 
 
1) This study shows that elevated SUA is strongly associated with an 
increased risk for the development of acute ischaemic / non-embolic  
stroke in this study population.  
2) The association between elevated SUA and ischaemic stroke may 
need to be considered especially when treating elderly patients, 
diabetics and the population with coronary artery disease. 
3) Elevated SUA can be considered as one of the risk factor for acute 
ischaemic non – embolic stroke.  
4) Lowering SUA level can be considered as one of the preventive 
modalities for stroke while treating high risk population.  
5) It is also suggested that further studies are required to assess whether 
lowering of SUA level with drugs can actually reduce the risk of 
ischaemic stroke.  
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 PROFORMA 
 
 
CASE NO 
 
Name :  
Age  :      Sex: M/F  
Address:  
Occupation:       Income: 
 
 
Socioeconomic status:     Handedness: R / L  
 
DOA:       DOD:  
 
 
PRESENT COMPLAINTS: 
 
H / O Present Illness: 
 Duration -     
            Seizures: Y / N    
            ICT Features: Y / N  
 H / O   LOC : Y / N  
 S / O higher functions abnormality: 
 s/o cranial nerve lesions: 
 s/o motor system abnormalities: 
 s/o sensory involvement:  
 s/o cerebellar involvement: 
 s/o EPS involvement: 
 
 
 
 PAST HISTORY 
  HTN  - Y / N  DM – Y/N      CAD-Y/N   
             CVA-Y/N              TIA-Y/N  
 GOUT – Y/N  Hyperlipidemia – Y / N  
 
PERSONAL HISTORY 
 
 SMOKING -     ALCOHOLISM 
  Diet – Veg/Non veg / Mixed    
            DRUG INTAKE – Thiazide diuretic 
 
FAMILY HISTORY 
 
 DM -   ; HTN  ; CAD  ; TIA   ;CVA  GOUT 
 
CLINICAL EXAMINATION: 
(a) VITALS:              Pulse -       /mt;   BP-   mm of Hg 
(b) Higher functions:  Consciousness; 
Memory  : 
Speech  : 
Behavior  :  
(c) Cranial nerves :  
 
 
 
 
(d) SPINOMOTOR SYSTEM:    R   L 
                             Bulk of muscle   UL  
                                                                   LL 
                             Tone    UL  
                                                                   LL 
             
                                                                               R             L    
                               Power    UL  
                                                                   LL  
                                 DTR    UL  
                                                                   LL                                                               
                              Plantar     
 
(e) SENSORY SYSTEM  
(f) CEREBELLUM:  
(g) EPS   :  
(h) SPINE / CRANIUM:  
 
 
OTHER SYSTEMS:  
(a) CVS   : 
(b) RS   : 
(c) P / A   : 
 
 
Diagnosis – CVA -   Anterior circulation  
    Posterior circulation  
    Territory – ACA / MCA  
 
 
 
 
 
 
 
 
 
 
  
 
 
INVESTIGATIONS:  
 
1. Blood   : TC -   cells/cu.mm   2. Urine: Alb –  
  DC – P    L     E     %     Sug- 
Hb -   gms/dl     Dep-  
 
3. Blood:   Sugar -  mgsdl              Urea –           mg/dl 
                                  Creatinine       mg/dl  
 
 
4. Lipid profile – TGL mgs/dl                   LDL 
              TC                                HDL 
 
5. Serum uric acid –  
 
 
6. ECG in all leads –  
 
 
7.  CT Brain Plain              INFARCT REGION –  
    INFARCT SIZE –  
 
8. CARDIAC EVALUATION – 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to participate in 
the study conducted by DR .S.VISHNU PRASAD, Post graduate in the Department of  
General Medicine ,Thanjavur Medical College & Hospital, Thanjavur – 613004 and to use 
my personal clinical data and result of investigation for the purpose of analysis and to study 
the nature of disease. I also give consent for further investigations 
 
 
Place : 
Date :        
               
 
                                                                                          Signature of participant 
 
 
 
 
SI.NO AGE SEX HTN DM SMOKING CAD DYSLIPIDEMIA ALCOHOLISM DIET URIC ACID
<5 5-6.9 >7
1 46 Male Absent Absent Yes Absent Present Yes Mixed 3.5   -    -
2 79 Male Absent Absent Yes Absent Absent No Mixed   -   - 8.3
3 48 Male Absent Absent Yes Absent Present Yes Mixed 2.7   -   -
4 51 Male Absent Absent Yes Absent Absent No Mixed 4.1   -   -
5 54 Male Present Present Yes Absent Present No Mixed   - 6.3   -
6 57 Female Absent Absent No Absent Absent No Mixed 4.2   -   -
7 79 Male Present Present No Present Absent No Mixed   -   - 8.2
8 64 Female Absent Present No Present Present No Mixed 4.7   -   -
9 59 Male Present Absent No Absent Present No Mixed 4.4   -   -
10 63 Female Absent Absent No Absent Absent No Mixed 3.8   -   -
11 77 Female Absent Present No Absent Absent No Veg   - 5.5   -
12 41 Female Absent Absent No Absent Absent No Mixed 4.1   -   -
13 62 Male Absent Present No Absent Absent No Mixed   - 6.1   -
14 53 Male Present Absent Yes Absent Absent No Mixed   - 5.3   -
15 51 Male Absent Absent Yes Absent Absent No Mixed 3.5   -   -
16 62 Female Present Present No Absent Absent No Veg   - 5.5   -
17 68 Male Absent Present No Absent Absent Yes Mixed   - 6.4   -
18 49 Male Present Absent No Absent Absent No Mixed 4.1   -   -
19 76 Male Absent Present No Present Present No Mixed   -   - 8.5
20 69 Female Present Absent No Present Absent Yes Mixed   -   - 7.4
21 63 Female Present Present Yes Present Absent Yes Mixed   - 6.2   -
22 59 Female Present Absent No Absent Absent No Mixed 4.6   -   -
23 72 Female Absent Absent No Absent Absent No Mixed   -   - 7.2
24 82 Male Present Present No Absent Absent No Mixed   - 5.4   -
25 48 Male Absent Absent No Absent Absent No Mixed 3.9   -   -
26 72 Female Present Present No Present Present No Veg   -   - 8.9
27 60 Female Present Absent No Absent Absent No Mixed 4.5   -   -
SI.NO AGE SEX HTN DM SMOKING CAD DYSLIPIDEMIA ALCOHOLISM DIET URIC ACID
28 71 Male Present Present No Absent Absent No Mixed   - 5.1   -
29 62 Male Present Absent Yes Present Absent Yes Mixed   -   - 8.7
30 41 Female Absent Absent No Absent Absent No Mixed 3.6   -   -
31 46 Male Absent Present No Absent Present No Veg 4.9   -   -
32 53 Male Present Absent Yes Absent Absent Yes Mixed 4.1   -   -
33 61 Male Present Absent No Absent Absent Yes Mixed 2.7   -   -
34 56 Male Absent Present Yes Present Present Yes Mixed   -   - 8.1
35 55 Male Present Absent Yes Present Absent Yes Veg   - 6.4   -
36 59 Female Present Absent No Present Absent No Mixed   -   - 7.4
37 61 Female Absent Present No Present Present No Mixed   - 6.7   -
38 58 Male Present Absent Yes Absent Absent Yes Mixed   - 5.7   -
39 52 Male Absent Absent Yes Absent Absent Yes Mixed 3   -   -
40 43 Male Present Absent Yes Absent Present No Mixed 4.2   -   -
41 57 Male Present Absent Yes Absent Absent Yes Mixed 3.8   -
42 75 Male Present Present No Present Absent No Mixed   -   - 9.1
43 59 Male Present Present Yes Present Present No Veg   -   - 8.3
44 64 Female Absent Present No Absent Absent No Mixed   - 5.9   -
45 65 Female Present Present No Absent Absent No Mixed   -   - 7.1
46 42 Female Absent Absent No Absent Present No Mixed 3.7   -   -
47 56 Male Absent Absent Yes Absent Absent No Mixed 4   -   -
48 60 Male Present Absent Yes Absent Absent No Mixed   - 5.5   -
49 54 Male Present Absent Yes Absent Absent Yes Mixed 4.5   -   -
50 74 Male Present Absent Yes Absent Absent Yes Mixed 4.1   -   -
51 48 Male Present Present Yes Absent Present Yes Mixed   -   - 8.1
52 57 Male Present Present No Present Present No Veg   -   - 7.4
53 70 Female Present Absent No Absent Absent No Mixed   -   - 8.3
54 55 Male Present Present No Present Absent No Mixed   - 5.1   -
55 65 Female Present Present No Absent Absent No Mixed   - 5.6   -
SI.NO AGE SEX HTN DM SMOKING CAD DYSLIPIDEMIA ALCOHOLISM DIET URIC ACID
56 69 Female Present Present No Absent Present No Mixed 4.8   -   -
57 41 Female Present Present No Present Absent No Mixed 3.7   -   -
58 49 Female Present Absent No Absent Absent No Mixed 4.3   -   -
59 83 Female Present Present No Present Absent No Mixed 4.2   -   -
60 42 Female Present Absent No Absent Absent No Mixed   - 5.5   -
61 63 Male Present Absent No Absent Absent No Veg 4.7   -   -
62 70 Male Absent Absent No Absent Absent No Mixed   -   - 9.2
63 66 Male Present Absent Yes Absent Absent No Mixed   - 5.1   -
64 51 Female Present Absent No Absent Absent No Mixed 3.5   -   -
65 55 Male Present Present Yes Absent Absent No Mixed 4.6   -   -
66 69 Female Present Present No Absent Present No Mixed   -   - 7.3
67 64 Female Absent Absent No Absent Absent No Mixed 4.8   -   -
68 62 Male Present Present Yes Present Present Yes Mixed 3.8   -   -
69 64 Female Present Absent No Absent Absent No Mixed   - 5.3   -
70 41 Male Absent Absent Yes Present Present No Mixed 3.9   -   -
71 80 Male Present Present Yes Present Present Yes Mixed   -   - 8.3
72 50 Male Absent Absent Yes Absent Absent No Mixed 4.3   -   -
73 46 Male Present Present Yes Absent Present No Mixed 2.5   -   -
74 65 Female Absent Absent No Present Absent No Mixed 2.7   -   -
75 73 Female Present Absent No Present Absent No Veg 4.1   -   -
76 71 Female Present Absent No Absent Absent No Mixed   -   - 7.1
77 70 Female Present Present No Present Absent No Mixed   -   - 7.5
78 63 Female Present Present No Absent Present No Mixed   - 6.3   -
79 61 Male Present Present Yes Present Present Yes Mixed   -   - 7.1
80 60 Male Present Absent Yes Absent Present No Mixed 4.6   -   -
81 68 Male Present Absent Yes Present Absent No Mixed   - 5.4   -
82 62 Female Present Present No Absent Present No Veg   - 6.3   -
83 58 Female Present Present No Present Present No Veg   -   - 7.5
SI.NO AGE SEX HTN DM SMOKING CAD DYSLIPIDEMIA ALCOHOLISM DIET URIC ACID
84 80 Female Present Absent No Absent Absent No Mixed   - 5.3   -
85 67 Female Present Present No Present Present No Mixed   -   - 8.7
86 56 Female Absent Present No Absent Present No Mixed 4.7   -   -
87 63 Female Present Present No Present Present No Mixed 3.7   -   -
88 44 Female Absent Absent No Absent Absent No Mixed   - 5.4   -
89 45 Female Absent Present No Absent Present No Mixed 4.3   -   -
90 65 Female Present Absent No Absent Absent No Mixed 4.1   -   -
91 74 Female Present Present No Present Absent No Mixed   -   - 7.2
92 56 Male Present Present Yes Absent Absent Yes Mixed 3.8   -   -
93 63 Female Present Present No Present Present No Mixed   -   - 7.1
94 47 Female Present Present No Present Absent No Mixed 4.8   -   -
95 56 Female Present Absent No Present Absent No Mixed 4.6   -   -
96 51 Female Present Present No Present Present No Veg   - 5.1   -
97 57 Male Present Absent Yes Absent Absent No Mixed 3.7   -   -
98 48 Female Absent Present No Absent Present No Mixed   - 5.4   -
99 65 Female Absent Present No Absent Absent No Mixed   - 6.7   -
100 48 Female Absent Present No Absent Present No Mixed 4.3   -   -
